First participant recruited to MIROCALS trial The MIROCALS consortium is delighted to announce that the first participant has been recruited to the MIROCALS trial, at Hospices Civils de Lyon, France. Read more. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 633413. Gilbert BensimonGilbert is …
The MIROCALS consortium is delighted to announce that the first participant has been recruited to the MIROCALS trial, at Hospices Civils de Lyon, France. “We are very pleased to be entering the recruitment phase. Many of the other participating clinics in France and England are undergoing their final readiness checks and we expect the majority …
MIROCALS 2nd General meeting in Milan, June 2018 During the last consortium meeting of MIROCALS held on June 7th and 8th 2018 in the Humanitas Congress Centre in Milano (Italy), the progress made since the beginning of the project were presented. This project has received funding from the European Union’s Horizon 2020 research and innovation programme …
MIROCALS 1st General Assembly meeting in Brighton, June 2016 This meeting gathered all MIROCALS partners for presenting the progress made since the launch of the project a year ago as well as the next achievements for the coming year. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under …
7th ExCom, Autumn 2019 The 7th Executive Committee Meeting will be held next autumn to discuss about the progress since the last meeting and to plan the next activities. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 633413. Gilbert BensimonGilbert is a biotechnologist specializing …
Spreading the word about MIROCALS In mid-February, Prof Nigel leigh (Brighton and Sussex Medical School) and Dr Brian Dickie (Motor Neurone Disease Association) took part in a webinar to promote awareness of ALS and the MIROCALS trial. The webinar, titled ‘A Novel Approach to ALS Trial Development’ was hosted by Icon PLC (the company employed …
6th ExCom, March 2019 The 6th Executive Committee Meeting took place on 15th March 2019 to discuss about the progress since the last meeting and to plan the next activities. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 633413. Gilbert BensimonGilbert is a biotechnologist …
Will Brexit impact on MIROCALS? As with everything else affected by Brexit, there are probably more questions than answers! The most important issue is funding and we can reassure all trial participants that the funding from the European Commission for MIROCALS will not be affected by the United Kingdom leaving the European Union. The most …
Major advances not only for ALS but other neurodegenerative diseasesIf positive, MIROCALS will be offering a new therapeutic strategy with a high potential to generate major advances in clinical practice for ALS and for other chronic neurodegenerative diseases. Even if low-dose IL-2 does not slow down the progression of ALS, the project will deliver many …
Context Also known as amyotrophic lateral sclerosis (ALS), MND is a fatal, rapidly progressive disease that affects the brain and spinal cord. It attacks the nerves that control movement; people can still think and feel, but their muscles refuse to work. It can leave people locked in a failing body, unable to move, talk, and …